Literature DB >> 17213339

The genotype 3-specific hepatitis C virus core protein residue phenylalanine 164 increases steatosis in an in vitro cellular model.

C Hourioux1, R Patient, A Morin, E Blanchard, A Moreau, S Trassard, B Giraudeau, P Roingeard.   

Abstract

BACKGROUND AND AIMS: The prevalence and severity of liver steatosis are higher in patients infected with genotype 3 hepatitis C virus (HCV) than in patients infected with other genotypes. HCV core protein is known to affect lipid metabolism, inducing lipid droplet accumulation both in vitro and in vivo. An in vitro cellular model was used to investigate whether an HCV core protein with residues specific to genotype 3 increased this phenomenon.
METHODS: Sequence comparisons for HCV core protein domain II, which is known to interact with lipid droplets, identified the phenylalanine (F) residue at position 164 as the only residue specific to genotype 3. The area covered by lipid droplets in sections of cells producing a wild-type genotype 1a HCV core protein was compared with that in cells producing a Y164F mutant protein.
RESULTS: Cumulative lipid droplet area was significantly greater in sections of cells producing the Y164F mutant HCV core protein than in cells producing the wild-type protein (p<0.001). The frequency of cell sections containing more than 3 mum(2) of lipid droplets, in particular, was higher for the mutant than for the wild-type protein.
CONCLUSION: The data provide a molecular explanation for HCV genotype 3-specific lipid accumulation. This difference between genotypes may be due to phenylalanine having a higher affinity for lipids than tyrosine (Y). These observations provide useful information for further studies of the mechanisms involved in HCV-induced steatosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17213339      PMCID: PMC2267372          DOI: 10.1136/gut.2006.108647

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  40 in total

1.  Hepatitis C virus-like particle morphogenesis.

Authors:  Emmanuelle Blanchard; Denys Brand; Sylvie Trassard; Alain Goudeau; Philippe Roingeard
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

2.  Activation of the interferon-inducible protein kinase PKR by hepatocellular carcinoma derived-hepatitis C virus core protein.

Authors:  N Delhem; A Sabile; R Gajardo; P Podevin; A Abadie; M A Blaton; D Kremsdorf; L Beretta; C Brechot
Journal:  Oncogene       Date:  2001-09-13       Impact factor: 9.867

3.  Intramembrane proteolysis promotes trafficking of hepatitis C virus core protein to lipid droplets.

Authors:  John McLauchlan; Marius K Lemberg; Graham Hope; Bruno Martoglio
Journal:  EMBO J       Date:  2002-08-01       Impact factor: 11.598

4.  Hepatitis C virus-like particle budding: role of the core protein and importance of its Asp111.

Authors:  Emmanuelle Blanchard; Christophe Hourioux; Denys Brand; Malika Ait-Goughoulte; Alain Moreau; Sylvie Trassard; Pierre-Yves Sizaret; Frederic Dubois; Philippe Roingeard
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

5.  Steatosis affects chronic hepatitis C progression in a genotype specific way.

Authors:  L Rubbia-Brandt; P Fabris; S Paganin; G Leandro; P-J Male; E Giostra; A Carlotto; L Bozzola; A Smedile; F Negro
Journal:  Gut       Date:  2004-03       Impact factor: 23.059

6.  Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

Authors:  Thierry Poynard; Vlad Ratziu; John McHutchison; Michael Manns; Zachary Goodman; Stefan Zeuzem; Zobair Younossi; Janice Albrecht
Journal:  Hepatology       Date:  2003-07       Impact factor: 17.425

7.  Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response.

Authors:  Dinesh Kumar; Geoffrey C Farrell; Caroline Fung; Jacob George
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

8.  Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies.

Authors:  L Castéra; C Hézode; F Roudot-Thoraval; A Bastie; E-S Zafrani; J-M Pawlotsky; D Dhumeaux
Journal:  Gut       Date:  2003-02       Impact factor: 23.059

9.  Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol.

Authors:  Alexander Monto; Judy Alonzo; Jessica J Watson; Carl Grunfeld; Teresa L Wright
Journal:  Hepatology       Date:  2002-09       Impact factor: 17.425

10.  Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins.

Authors:  Stephanie T Shi; Stephen J Polyak; Hong Tu; Deborah R Taylor; David R Gretch; Michael M C Lai
Journal:  Virology       Date:  2002-01-20       Impact factor: 3.616

View more
  28 in total

1.  "Liverscore" is predictive of both liver fibrosis and activity in chronic hepatitis C.

Authors:  Shoukat Ali Arain; Qamar Jamal; Amir Omair
Journal:  World J Gastroenterol       Date:  2011-11-07       Impact factor: 5.742

2.  Increased hepatic expression of miRNA-122 in patients infected with HCV genotype 3.

Authors:  Ketti G Oliveira; Fernanda M Malta; Ana C S S Nastri; Azzo Widman; Paola L Faria; Rúbia A F Santana; Venâncio A F Alves; Flair J Carrilho; João R R Pinho
Journal:  Med Microbiol Immunol       Date:  2015-08-14       Impact factor: 3.402

3.  Fatty liver in chronic hepatitis C infection: unravelling the mechanisms.

Authors:  Jude A Oben; Emma Paulon
Journal:  Gut       Date:  2007-09       Impact factor: 23.059

Review 4.  Adiponectin serum level in chronic hepatitis C infection and therapeutic profile.

Authors:  Valentina Peta; Carlo Torti; Natasa Milic; Alfredo Focà; Ludovico Abenavoli
Journal:  World J Hepatol       Date:  2015-01-27

5.  Ultrastructural and quantitative analysis of the lipid droplet clustering induced by hepatitis C virus core protein.

Authors:  Marion Depla; Rustem Uzbekov; Christophe Hourioux; Emmanuelle Blanchard; Amélie Le Gouge; Ludovic Gillet; Philippe Roingeard
Journal:  Cell Mol Life Sci       Date:  2010-04-27       Impact factor: 9.261

6.  Origin of hepatitis C virus genotype 3 in Africa as estimated through an evolutionary analysis of the full-length genomes of nine subtypes, including the newly sequenced 3d and 3e.

Authors:  Chunhua Li; Ling Lu; Donald G Murphy; Francesco Negro; Hiroaki Okamoto
Journal:  J Gen Virol       Date:  2014-05-02       Impact factor: 3.891

7.  Inhibition of core gene of HCV 3a genotype using synthetic and vector derived siRNAs.

Authors:  Saba Khaliq; Shah Jahan; Bushra Ijaz; Waqar Ahmad; Sultan Asad; Asim Pervaiz; Baila Samreen; Mahwish Khan; Sajida Hassan
Journal:  Virol J       Date:  2010-11-13       Impact factor: 4.099

Review 8.  Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen.

Authors:  Amedeo Lonardo; Luigi Elio Adinolfi; Luciano Restivo; Stefano Ballestri; Dante Romagnoli; Enrica Baldelli; Fabio Nascimbeni; Paola Loria
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 9.  Production and pathogenicity of hepatitis C virus core gene products.

Authors:  Hui-Chun Li; Hsin-Chieh Ma; Chee-Hing Yang; Shih-Yen Lo
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

10.  Palmitoylation of hepatitis C virus core protein is important for virion production.

Authors:  Nathalie Majeau; Rémi Fromentin; Christian Savard; Marie Duval; Michel J Tremblay; Denis Leclerc
Journal:  J Biol Chem       Date:  2009-09-16       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.